Rezvilutamide

Small molecule

Also known as SHR3680

Phase 3underway

Evidence outlook · registrational

Prostate Cancer: registrational readout pending

No completed mid-stage readout is on record. Registrational readout expected around 2027-03.

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.

Phase 3 (5)
Prostate Cancer
NCT07241416 · Jiangsu HengRui Medicine Co., Ltd.
2025-12-05 – 2028-09 · Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
What this study did
NCT05983783 · The First Affiliated Hospital with Nanjing Medical University
2023-08-01 – 2027-12-31 · Metastatic Prostate Cancer, Hormone Sensitive Prostate Cancer, Chemotherapy Effect
What this study did
NCT05956639 · The First Affiliated Hospital with Nanjing Medical University
2023-06-20 – 2027-12-31 · Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
What this study did
NCT03520478 · Jiangsu HengRui Medicine Co., Ltd.
2018-05-30 – 2025-04-30 · Prostate Cancer, Hormone-Dependent Prostate Cancer
What this study did
NCT05009290 · Jiangsu HengRui Medicine Co., Ltd.
2021-11-01 – 2024-09-06 · Patients With High-risk Localized or Locally Advanced Prostate Cancer Who Are Candidates for Radical Prostatectomy
What this study did
Phase 2 (12)
Prostate Cancer
NCT05406999 · The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
2020-02-01 – 2030-06-30 · Neoadjuvant Therapy, High Risk Prostate Cancer, Locally Advanced Prostate Cancer, Intense Endocrine Therapy
What this study did
NCT07711314 · The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
2026-07-01 – 2030-05 · Prostate Cancer (Post Prostatectomy)
What this study did
NCT07230106 · Jiangsu HengRui Medicine Co., Ltd.
2025-12-08 – 2029-12 · Prostate Cancer
What this study did
NCT06387056 · The First Affiliated Hospital of Xiamen University
2024-04-01 – 2029-04-01 · Locally Advanced Prostate Cancer, Oligometastatic Prostate Cancer
What this study did
NCT07795177 · Anhui Medical University
2026-10-01 – 2028-06-30 · Metastatic Hormone-Sensitive Prostate Cancer
What this study did
NCT06305832 · The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
2023-09-07 – 2028-03 · Prostate Cancer, Biochemical Recurrence
What this study did
NCT05753566 · The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
2023-03 – 2028-03 · Prostate Cancer, Biochemical Recurrence
What this study did
NCT06134271 · Jianbin Bi
2023-11-15 – 2026-04-30 · Metastatic Hormone-Sensitive Prostate Cancer
What this study did
NCT06505278 · Sun Yat-sen University
2024-08 – 2025-12 · Prostate Cancer
What this study did
NCT04102124 · Jiangsu HengRui Medicine Co., Ltd.
2019-04-08 – 2021-08-31 · Prostate Cancer, Castration-resistant Prostate Cancer
What this study did
Other / comorbidity
NCT06348264 · Peking University First Hospital
2024-10-10 – 2031-03-30 · Salivary Gland Neoplasm Duct
What this study did
NCT04355858 · Fudan University
2020-05-01 – 2025-04-01 · Breast Cancer, Metastatic Cancer
What this study did
Phase 1/2 (4)
Prostate Cancer
NCT07407283 · Jiangsu HengRui Medicine Co., Ltd.
2026-04-08 – 2028-04 · Prostate Cancer
What this study did
NCT02691975 · Jiangsu HengRui Medicine Co., Ltd.
2016-04-12 – 2021-06-01 · Hormone Refractory Prostate Cancer, Metastatic Prostate Carcinoma
What this study did
NCT03741712 · Jiangsu HengRui Medicine Co., Ltd.
2018-11-20 – 2020-12-08 · Prostate Cancer, Castration-resistant Prostate Cancer
What this study did
Other / comorbidity
NCT05928780 · Fudan University
2023-07-01 – 2025-09-01 · TNBC - Triple-Negative Breast Cancer
What this study did
Phase 1 (7)
Prostate Cancer
NCT05607693 · Jiangsu HengRui Medicine Co., Ltd.
2023-04-26 – 2024-11-05 · Castration-Resistant Prostate Cancer
What this study did
NCT04676035 · Jiangsu HengRui Medicine Co., Ltd.
2020-06-15 – 2022-01-26 · Prostate Cancer Patients
What this study did
NCT04664725 · Jiangsu HengRui Medicine Co., Ltd.
2020-06-01 – 2021-05 · Prostate Cancer Patients
What this study did
NCT02747342 · Atridia Pty Ltd.
2016-09 – 2020-06-28 · Neoplasm, Prostate Cancer
What this study did
Other / comorbidity
NCT04631549 · Jiangsu HengRui Medicine Co., Ltd.
2021-02-03 – 2023-07 · Hepatic Impairment, Healthy Participants
What this study did
NCT04621669 · Jiangsu HengRui Medicine Co., Ltd.
2021-01-08 – 2021-09-08 · Drug-drug Interaction,SHR3680
What this study did
NCT04903158 · Jiangsu HengRui Medicine Co., Ltd.
2021-01-06 – 2021-05 · Healthy Male Subjects
What this study did
Early phase / not applicable (2)
Prostate Cancer
NCT07444983 · Fujian Medical University Union Hospital
2026-02-11 – 2029-07-11 · Prostate Cancer (Adenocarcinoma)
What this study did
NCT07112209 · Zhujiang Hospital
2023-11-06 – 2027-11-06 · Pathological and Imaging Examinations Confirmed Metastatic Prostate Cancer
What this study did
Used as active comparator (1)

Other programs' studies in which this drug was the registered active-comparator arm: a marker of standard-of-care status, not evidence of this drug's own progression.

Phase 2 (1)
Prostate Cancer
NCT04603833 · Jiangsu HengRui Medicine Co., Ltd.
2020-12-02 – 2022-12-31 · Prostate Cancer Metastatic
What this study did
Appears in other studies (2)

Studies that reference this drug without giving it an intervention arm of its own: other formulations' programs, background therapy, or registry-search bleed.

Phase 2 (2)
Prostate Cancer
NCT07490210 · Fudan University
2026-05-01 – 2032-05-31 · Oligometastatic Prostate Cancer
What this study did
NCT06832774 · Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
2025-08-01 – 2028-12-31 · Prostate Cancer Metastatic Disease
What this study did

Competitive landscape

1 other tracked programme targets this mechanism, none of them ahead of this one.

This drug's own stage for Prostate Cancer: Phase 3. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Rezvilutamide: this drugPhase 3Small moleculeAndrogen receptornot yet gradedNo reviewed efficacy summary in this indication
CapivasertibApprovedSmall moleculeAKT (inhibitor)not yet gradedNo reviewed efficacy summary in this indication
Docetaxel (Taxotere)ApprovedSmall moleculeMicrotubules (tubulin)not yet gradedNo reviewed efficacy summary in this indication
OlaparibApprovedSmall moleculePARPnot yet gradedNo reviewed efficacy summary in this indication
RucaparibApprovedSmall moleculePARP (poly ADP-ribose polymerase) enzymes, PARP1/2Partial signalNo reviewed efficacy summary in this indication
TalazoparibApprovedSmall moleculePARPnot yet gradedNo reviewed efficacy summary in this indication
225Ac-PSMA-617Phase 3Radioligand Therapy (actinium-225)PSMAnot yet gradedNo reviewed efficacy summary in this indication
CabozantinibPhase 3Small moleculeMET / VEGFR / AXL / RET (multi-kinase)not yet gradedNo reviewed efficacy summary in this indication
JNJ-101556143Phase 3Small molecule—not yet gradedNo reviewed efficacy summary in this indication
JNJ-87189401Phase 3Undisclosed—not yet gradedNo reviewed efficacy summary in this indication
RinzimetostatPhase 3Small moleculeEED (PRC2)not yet gradedNo reviewed efficacy summary in this indication
SaruparibPhase 3Small moleculePARP1 inhibitor (next-gen)not yet gradedNo reviewed efficacy summary in this indication
Abiraterone DecanoatePhase 2Small moleculeCYP17 lyasenot yet gradedNo reviewed efficacy summary in this indication
HRS-5041Phase 2Small moleculeAndrogen receptor (degrader)not yet gradedNo reviewed efficacy summary in this indication
Luxdegalutamide
Phase 2(overall)
Small moleculeAndrogen receptor, Androgen receptor (degrader)
not yet graded(overall)
No reviewed efficacy summary in this indication
MRT-2359Phase 2Small moleculeGSPT1not yet gradedNo reviewed efficacy summary in this indication
AMO959Phase 1/2Small moleculeDNA-PKnot yet gradedNo reviewed efficacy summary in this indication
AZD0516Phase 1/2Antibody–drug conjugateSTEAP2not yet gradedNo reviewed efficacy summary in this indication
AZD0754Phase 1/2Cell therapySTEAP2not yet gradedNo reviewed efficacy summary in this indication
AZD6621Phase 1/2Multispecific antibodySTEAP2 x CD3not yet gradedNo reviewed efficacy summary in this indication
HRS-1738Phase 1/2UndisclosedPSMAnot yet gradedNo reviewed efficacy summary in this indication
NezastomigPhase 1/2Multispecific antibodyPSMA x CD28not yet gradedNo reviewed efficacy summary in this indication
OlsutamigPhase 1/2Multispecific antibodyPSMA x CD3not yet gradedNo reviewed efficacy summary in this indication
REGN15505Phase 1/2Multispecific antibodyPSMA x 4-1BBnot yet gradedNo reviewed efficacy summary in this indication
SHR-4394Phase 1/2Antibody–drug conjugatePSMAnot yet gradedNo reviewed efficacy summary in this indication
AZD2284Phase 1Radioconjugate (actinium-225)STEAP2not yet gradedNo reviewed efficacy summary in this indication
BMS-986460Phase 1Undisclosed—not yet gradedNo reviewed efficacy summary in this indication
INR731Phase 1Undisclosed—not yet gradedNo reviewed efficacy summary in this indication
JANX007Phase 1Multispecific antibodyPSMA x CD3not yet gradedNo reviewed efficacy summary in this indication
JNJ-95298177Phase 1Antibody–drug conjugate—not yet gradedNo reviewed efficacy summary in this indication
JNJ-98768111Phase 1Undisclosed—not yet gradedNo reviewed efficacy summary in this indication
VIR-5500Phase 1Multispecific antibodyPSMA x CD3not yet gradedNo reviewed efficacy summary in this indication
GSK5471713
—(overall)
UndisclosedAndrogen receptor (degrader)not yet gradedNo reviewed efficacy summary in this indication
RG6537
—(overall)
Undisclosed—not yet gradedNo reviewed efficacy summary in this indication
SHR-7525
—(overall)
Undisclosed—not yet gradedNo reviewed efficacy summary in this indication

Upcoming events

(11 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Rezvilutamide to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (1)
December 2026 (1)
Phase 2Prostate CancerRecruiting
Est. primary completion 2026-12-31 · NCT05406999 · CT.gov ↗
What to watch
2027 (6)
February 2027 (1)
Early phase / not applicableProstate CancerNot yet recruiting
Est. primary completion 2027-02-11 · NCT07444983 · CT.gov ↗
What to watch
March 2027 (2)
Phase 2Prostate CancerRecruiting
Est. primary completion 2027-03 · NCT05753566 · CT.gov ↗
What to watch
Phase 3Prostate CancerRecruiting
Est. primary completion 2027-03 · NCT07241416 · CT.gov ↗
What to watch
May 2027 (1)
Phase 2Prostate CancerRecruiting
Est. primary completion 2027-05 · NCT07711314 · CT.gov ↗
What to watch
June 2027 (1)
Early phase / not applicableProstate CancerEnrolling by invitation
Est. primary completion 2027-06-10 · NCT07112209 · CT.gov ↗
What to watch
November 2027 (1)
Phase 1/2Prostate CancerRecruiting
Est. primary completion 2027-11 · NCT07407283 · CT.gov ↗
What to watch
2028 (3)
March 2028 (1)
Phase 2Prostate CancerRecruiting
Est. primary completion 2028-03 · NCT06305832 · CT.gov ↗
What to watch
April 2028 (1)
Phase 2Prostate CancerNot yet recruiting
Est. primary completion 2028-04-30 · NCT07795177 · CT.gov ↗
What to watch
December 2028 (1)
Phase 2Prostate CancerRecruiting
Est. primary completion 2028-12 · NCT07230106 · CT.gov ↗
What to watch
2029 (1)
March 2029 (1)
Phase 2Salivary Gland Neoplasm DuctRecruiting
Est. primary completion 2029-03-30 · NCT06348264 · CT.gov ↗
What to watch

See the full readout calendar ↗